Nanomedicine to deliver biological macromolecules for treating COVID-19

Coronavirus disease (COVID-19) was first reported in December 2019, China and later it was found that the causative microorganism is severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). As on 3rd June 2021, SARS-CoV-2 has affected 171049741 people worldwide with 3549710 deaths. Nanomedicine...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2022-06, Vol.40 (29), p.3931-3941
Main Authors: Wilson, Barnabas, Mukundan Geetha, Kannoth
Format: Article
Language:English
Subjects:
Antiviral Agents - therapeutic use
Coronaviruses
COVID-19
COVID-19 Drug Treatment
Drugs
Humans
Lipids
Liposomes
Macromolecules
Middle East respiratory syndrome
Nanocarriers
Nanomedicine
Nanoparticles
Nanotechnology
Review
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Vaccines
Viral diseases
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Coronavirus disease (COVID-19) was first reported in December 2019, China and later it was found that the causative microorganism is severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). As on 3rd June 2021, SARS-CoV-2 has affected 171049741 people worldwide with 3549710 deaths. Nanomedicine such as nanoparticles, liposomes, lipid nanoparticles, virus-like nanoparticles offer tremendous hopes to treat viral infections including COVID-19. Most importantly target specific ligands can be attached on the surface of them and this makes them more target specific and the loaded drug can be delivered to cellular and molecular level. These properties of nanomedicines can be utilized to deliver drugs or vaccines to treat viral diseases including SARS-CoV-2 infection. This review discusses about SARS-CoV-2 and the potential application of nanomedicines for delivering biological macromolecules like vaccines and drugs for treating COVID-19.
ISSN:0264-410X
1873-2518
1873-2518
DOI:10.1016/j.vaccine.2022.05.068